Endocrine and Metabolic

(144) Racial Disparities associated with Total Healthcare Expenditures (THEs) in Type 2 Diabetes Mellitus (T2DM): Impact of GLP1 RAs

(147) Expected vs observed mortality rates, expressed as number needed to treat, from a Phase 3 clinical trial program of patients with hyperphagia and Prader-Willi Syndrome treated with diazoxide choline extended release (DCCR)

(148) The burden of Prader-Willi Syndrome on patients and the healthcare system: a cross-sectional examination of emergency department visits and inpatient stays in US claims

(150) Efficacy of elinzanetant in previous or never users of HT: pooled analysis

(151) Modelling Total Healthcare Cost Offsets and Treatment Costs Associated with Treating Adults with Obesity with Tirzepatide and Semaglutide in US Clinical Practice Settings

(154) The impact of vasomotor symptoms on women in the workplace in the United States of America: results of an online survey

(155) Cost-effectiveness analysis of somapacitan-beco versus somatropin in the treatment of patients with pediatric growth hormone deficiency (GHD) in the United States

(159) Comparing the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on the incidence of neuropathy in patients with type 2 diabetes

(160) Trends in Characteristics and Anti-Obesity Medication Use Among US Employees in the Era of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)